HealthPharma & Biotech
Starpharma Holdings Limited

Starpharma Holdings to finalise equity capital raising


Starpharma Holdings (ASX:SPL) has been granted a trading halt by the ASX this morning, pending the finalisation of an equity capital raising.

Starpharma is an ASX 300 company with a focus on the development of dendrimer products for pharmaceutical, life science and other applications.

The halt will remain in place until the opening of trade on Wednesday 9th December 2015, or earlier if an announcement is made to the market.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Starpharma Holdings Limited

Price: $1.24

Market: ASX
Market Cap: $460.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian...

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer. The CEO said the first part of the study has shown some very...

3 hours, 1 minute ago

2 min read